Information Provided By: 
Fly News Breaks for March 6, 2018
ANTH
Mar 6, 2018 | 08:46 EDT
H.C. Wainwright analyst Andrew Fein continues to like the risk/reward equation on shares of Anthera Pharmaceuticals heading into this month's Sollpura data readout. The analyst believes the Result trial's more dose-tailoring, time, and patients allow greater room for optimization and achieving max therapeutic effect. He believes "very little positivity" is now reflected in the shares, and expects an "outsized move to the upside" should a positive result be announced later this month. Fein has a Buy rating on Anthera with a $3 price target.
News For ANTH From the Last 2 Days
There are no results for your query ANTH
